GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After ...
August 16 2016 - 9:15AM
Business Wire
- Research shows effectiveness in
stabilizing atherosclerotic plaques, reducing risk of further
injury due to reduced blood flow
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the
publication of results from a preclinical study that showed its
drug candidate GMI-1271 reduced the cellular interactions that
often lead to a buildup in inflammatory response and unstable
atherosclerotic plaque formation after a heart attack. The study,
entitled “E-Selectin Inhibition Mitigates Splenic HSC Activation
and Myelopoiesis in Hypercholesterolemic Mice With Myocardial
Infarction,” was published in the September issue of
Arteriosclerosis, Thrombosis, and Vascular Biology.
In the study, researchers demonstrated a wider range of
potential clinical applications of the E-selectin antagonist
GMI-1271, which is currently being evaluated as a potential
treatment for acute myelogenous leukemia (AML) in a Phase 1/2
clinical trial.
“The results in this animal model of myocardial infarction and
atherosclerosis demonstrate both the biological activity of
GMI-1271 and the possible broader uses of an E-selectin antagonist.
While GlycoMimetics is currently focused on developing GMI-1271 for
treatment of AML, this drug candidate has shown activity in
pre-clinical models of a number of diseases where E-selectin plays
a key functional role,” said John L. Magnani, Ph.D., Vice President
and Chief Scientific Officer of GlycoMimetics.
Myocardial infarctions are often triggered by unstable
atherosclerotic plaque material, the growth of which is initiated
by the production and infiltration of inflammatory cells through
the action of E-selectin. The study, conducted at Harvard Medical
School and Massachusetts General Hospital, found that after a
myocardial infarction (MI), GMI-1271 not only reduced the
production of inflammatory cells and their hematopoietic stem and
progenitor cells, but also their infiltration into atherosclerotic
plaques, thereby stabilizing existing plaques and decreasing the
risk of a further ischemic injury which can lead to a second MI.
The study showed that GMI-1271-induced E-selectin inhibition
significantly reduced the numbers of stem and progenitor cells
leading to reduced numbers of inflammatory monocytes, and
neutrophils in the blood. It also inhibited their infiltration into
existing plaques leading to the stabilization of atherosclerotic
plaques (smaller plaque size, reduced necrotic core area, and
thicker fibrous cap) after an MI in animal models.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on cancer and sickle cell disease. GlycoMimetics’ most advanced
drug candidate, rivipansel, a pan-selectin antagonist, is being
developed for the treatment of vaso-occlusive crisis in sickle cell
disease and is being evaluated in a Phase 3 clinical trial being
conducted by its strategic collaborator, Pfizer. GlycoMimetics’
wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is
being evaluated in an ongoing Phase 1/2 clinical trial as a
potential treatment for AML. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more at
www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics’ planned activities with respect to the clinical
development of its drug candidate GMI-1271. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
availability and timing of data from ongoing clinical trials, the
uncertainties inherent in the initiation of future clinical trials,
whether interim results from a clinical trial will be predictive of
the final results of the trial or results of early clinical trials
will be indicative of the results of future trials, expectations
for regulatory approvals, availability of funding sufficient for
GlycoMimetics’ foreseeable and unforeseeable operating expenses and
capital expenditure requirements, other matters that could affect
the availability or commercial potential of GlycoMimetics’ drug
candidates and other factors discussed in the “Risk Factors”
section of GlycoMimetics’ Annual Report on Form 10-K that was filed
with the U.S. Securities and Exchange Commission on February 29,
2016, and other filings GlycoMimetics makes with the Securities and
Exchange Commission from time to time. In addition, the
forward-looking statements included in this press release represent
GlycoMimetics’ views as of the date hereof. GlycoMimetics
anticipates that subsequent events and developments may cause its
views to change. However, while GlycoMimetics may elect to update
these forward-looking statements at some point in the future,
GlycoMimetics specifically disclaims any obligation to do so,
except as may be required by law. These forward-looking statements
should not be relied upon as representing GlycoMimetics’ views as
of any date subsequent to the date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160816005628/en/
GlycoMimeticsInvestor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024